Handa Pharmaceuticals (ROCO:6620) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6620 Handa Pharmaceuticals Inc ROCO:6620
86 GF Score
Price NT$84.50
GF Value NT$108.38
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Handa Pharmaceuticals Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

ROCO:6620
86GF Score
Handa Pharmaceuticals Inc ROCO:6620
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Handa Pharmaceuticals (ROCO:6620) Overvalued in 2026?

Based on GuruFocus' analysis, Handa Pharmaceuticals stock appears to be undervalued. The current stock price of NT$84.50 is trading 22% below its estimated GF Value™ of NT$108.38. GuruFocus considers Handa Pharmaceuticals to be Modestly Undervalued.

Key valuation signals for ROCO:6620:

  • Interest Received:
  • GF Value™: NT$108.38 vs. price of NT$84.50 (22% below fair value)
  • GF Score™: 86/100 with 2 warning signs

No single metric tells the full story. See the ROCO:6620 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Handa Pharmaceuticals Business Description

Address Nanke 3rd Road, 3F-1,3F-2, No.23, Xinshi Dist, Tainan, TWN, 74147
Handa Pharmaceuticals Inc is a Taiwan-based specialty pharmaceutical company. It is engaged in the development of niche drugs. The company focuses on the development of high-barrier/patentable niche products.
86GF Score

Get the complete analysis for ROCO:6620

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$84.50
Price
NT$108.38
GF Value